Clinical Data from Phase 1 PK/PD Study of Octreotide for Intranasal Delivery to be Presented at North American Neuroendocrine Tumor Society Symposium
Dauntless Pharmaceuticals Announces Positive Data from Phase 1 Study Investigating Octreotide Formulation for Intranasal Delivery
Dauntless Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Octreotide Formulation for Intranasal Delivery
New-Era Drug Rx: C-Corp Per Compound And Large Dose of Outsourcing
Outsourced Pharma, September 14, 2015
Dauntless Pharmaceuticals derives its difference with its C-Corp per compound drug-development model.
Fear Not: Sofinnova Backs ‘Dauntless’ Approach to Drug Development
BioWorld Today, July 22, 2015
Dauntless Pharmaceuticals had a smooth initial take-off, fueled by a $12 million series A supporting a single asset, and that’s just the way the San Diego-based company and backer Sofinnova Ventures plan to keep rolling off the runway.
BioPharma M&A: Capital Efficiency Drives Returns
Life Sci VC, May 15, 2015
Optimal and efficient biotech company capital funding is critical to value creation and maximizing returns.
VCs: Adding or Subtracting Value to Biotech Startups?
Life Sci VC, October 14, 2013
Beyond capital investment: key value-added contributions of a good venture capitalist group can greatly aid in the company’s value creation and success. Dauntless Pharmaceuticals has a strong venture capitalist group in Sofinnova Ventures.
New Biotech Corporate Structures: Possible Alternatives For Discovery Platforms and Product Financings
Life Sci VC, September 18, 2012
The advantages of an asset-centric model in biotech. The structure of Dauntless Pharmaceuticals is similar to the model described in this article.